ScripOver the past roughly three years, AstraZeneca PLC’s key oncology drugs, including for lung cancer, have been facing gathering clouds in China. Not only are Chinese homegrown rivals nibbling at market
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Vignette Gets Rights To BCMA×CD3 Bispec
ScripArriVent Biopharma, Inc. executed one of the first initial public offerings by a biopharmaceutical company in the US this year, primarily to fund its lead drug candidate firmonertinib, an EGFR tyrosi
ScripInnovent Biologics, Inc. and GenFleet Therapeutics on 21 August scored China’s first approval for a KRAS G12C inhibitor, the co-developed Dupert (fulzerasib), winning a head start over foreign and